Patents by Inventor Daqing Sun

Daqing Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of glucocorticoid receptor
    Patent number: 11208432
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: December 28, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
  • INHIBITORS OF GLUCOCORTICOID RECEPTOR
    Publication number: 20210395295
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 23, 2021
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • INHIBITORS OF GLUCOCORTICOID RECEPTOR
    Publication number: 20210379084
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: July 21, 2021
    Publication date: December 9, 2021
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • CD73 inhibitors
    Patent number: 11129841
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: September 28, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Erica L. Jackson, Daqing Sun, Qiuping Ye, Jared Moore
  • CD73 inhibitors
    Patent number: 11130778
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: September 28, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • Inhibitors of glucocorticoid receptor
    Patent number: 11124537
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 21, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
  • Inhibitors of glucocorticoid receptor
    Patent number: 11110103
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 7, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
  • Refractive Index Adjustment Structure, Color Filter Substrate, Display Panel and Display Apparatus
    Publication number: 20210223643
    Abstract: Disclosed are a refractive index adjustment structure, a color filter substrate, a display panel and a display apparatus. The refractive index adjustment structure includes an adjustment layer and at least one electrode layer. The adjustment layer and the at least one electrode layer are provided in a stacked manner. The at least one electrode layer is configured to be loaded with an electric signal, and the electric signal is capable of adjusting a refractive index of the adjustment layer.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 22, 2021
    Inventors: Ning LI, Jianming JIANG, Wei GU, Tengli WANG, Daqing SUN, Ganlin RUAN
  • VIA HOLE STRUCTURE, MANUFACTURING METHOD THEREOF, ELECTRONIC DEVICE, AND DISPLAY DEVICE
    Publication number: 20210225738
    Abstract: A via hole structure includes: a first conductive layer, an interlayer insulating layer, and a second conductive layer that are sequentially arranged, wherein the interlayer insulating layer is provided with a via hole, the second conductive layer is overlapped with the first conductive layer by the via hole, and at least part of a surface, in contact with the second conductive layer, of the interlayer insulating layer is uneven.
    Type: Application
    Filed: December 16, 2019
    Publication date: July 22, 2021
    Applicants: BOE Technology Group Co., Ltd., Mianyang BOE Optoelectronics Technology Co., Ltd.
    Inventors: Lei ZHANG, Daqing SUN, Wei QIU, Fangliang YAN
  • CD73 INHIBITORS
    Publication number: 20210214387
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 15, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20210179560
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: August 3, 2020
    Publication date: June 17, 2021
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • CD73 inhibitors
    Patent number: 11028120
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: June 8, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND USES THEREOF
    Publication number: 20210147472
    Abstract: The present invention relates generally to formulations and methods for treating cancer. Provided herein are formulations comprising substituted steroidal derivatives. The subject formulations are useful for the treatment of cancer.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 20, 2021
    Inventors: Valeria R. FANTIN, Qiuping YE, Belinda DE LEON, Daqing SUN, Sunil V. MHASKAR
  • CD73 INHIBITORS
    Publication number: 20210130389
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • CD73 INHIBITORS
    Publication number: 20210130390
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: December 8, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20210122730
    Abstract: Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 29, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Yosup REW, Daqing SUN, Qiuping YE, Haiying ZHOU, Hiroyuki KAWAI, Jared MOORE, Johnny PHAM, Kejia WU, Liusheng ZHU, Dennis YAMASHITA
  • ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS
    Publication number: 20210047344
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: March 4, 2019
    Publication date: February 18, 2021
    Applicant: AMGEN INC.
    Inventors: Gwenaella RESCOURIO, Ana GONZALEZ BUENROSTRO, Sean P. BROWN, Mike LIZARZABURU, Julio MEDINA, Salman Yojiro JABRI, Daqing SUN, Scott Preston SIMONOVICH, Xuelei YAN, Yihong LI, Yosup REW
  • CD73 INHIBITORS
    Publication number: 20210047359
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 18, 2021
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
  • INHIBITORS OF GLUCOCORTICOID RECEPTOR
    Publication number: 20210023095
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 28, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • INHIBITORS OF GLUCOCORTICOID RECEPTOR
    Publication number: 20210017219
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 21, 2021
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS